Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): An open-label, dose finding, and feasibility phase 1/2 trial

The Lancet Neurology

Volumn 14, Issue 5, 2015, Pages 469-477

  Pressler, Ronit M ^a   Boylan, Geraldine B ^b   Marlow, Neil ^a   Blennow, Mats ^c   Chiron, Catherine ^d,e   Cross, J Helen ^a   de Vries, Linda S ^f   Hallberg, Boubou ^c   Hellström Westas, Lena ^g   Jullien, Vincent ^d,e   Livingstone, Vicki ^b   Mangum, Barry ^h   Murphy, Brendan ^b   Murray, Deirdre ^b   Pons, Gerard ^d,e   Rennie, Janet ^a   Swarte, Renate ⁱ   Toet, Mona C ^f   Vanhatalo, Sampsa ^j   Zohar, Sarah ^k  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g UPPSALA UNIVERSITY   (Sweden)

^h DUKE CLINICAL RESEARCH INSTITUTE   (United States)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^k CENTRE DE RECHERCHE DES CORDELIERS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; BUMETANIDE; LOOP DIURETIC AGENT; PHENOBARBITAL;

ADD ON THERAPY; ANTICONVULSANT THERAPY; ARTICLE; DEHYDRATION; DOSE CALCULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ELECTROLYTE DISTURBANCE; FEASIBILITY STUDY; FEMALE; HEARING IMPAIRMENT; HUMAN; HYPOTENSION; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INFANT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN INTENSIVE CARE; OFF LABEL DRUG USE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEIZURE; TREATMENT OUTCOME; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; DRUG POTENTIATION; EARLY TERMINATION OF CLINICAL TRIAL; HYPOXIA-ISCHEMIA, BRAIN; SEIZURES; TREATMENT FAILURE;

BUMETANIDE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; EARLY TERMINATION OF CLINICAL TRIALS; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; INFANT, NEWBORN; MALE; PHENOBARBITAL; SEIZURES; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT FAILURE;

EID: 84928067645     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70303-5     Document Type: Article

References (32)

1. Guidelines on neonatal seizures 2011, WHO, World Health Organization, Geneva.
2. Silverstein FS, Jensen FE, Inder T, Hellström-Westas L, Hirtz D, Ferriero DM Improving the treatment of neonatal seizures: National Institute of Neurological Disorders and Stroke workshop report. J Pediatr 2008, 153:12-15.
3. Boylan GB, Stevenson NJ, Vanhatalo S Monitoring neonatal seizures. Semin Fetal Neonatal Med 2013, 18:202-208.
4. Ben Ari Y, Holmes GL Effects of seizures on developmental processes in the immature brain. Lancet Neurol 2006, 5:1055-1063.
5. Dzhala VI, Talos DM, Sdrulla DA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med 2005, 11:1205-1213.
6. Cleary RT, Sun H, Huynh T, et al. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS One 2013, 8:e57148.
7. Löscher W, Puskarjov M, Kaila K Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology 2013, 69:62-74.
8. Ward A, Heel RC Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984, 28:426-464.
9. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006, 117:1979-1987.
10. Lopez-Samblas AM, Adams JA, Goldberg RN, Modi MW The pharmacokinetics of bumetanide in the newborn infant. Biol Neonate 1997, 72:265-272.
11. Forge A, Schacht J Aminoglycoside antibiotics. Audiol Neurootol 2000, 5:3-22.
12. Sullivan JE, Witte MK, Yamashita TS, Myers CM, Blumer JL Dose-ranging evaluation of bumetanide pharmacodynamics in critically ill infants. Clin Pharmacol Ther 1996, 60:424-434.
13. Azzopardi DV, Strohm B, Edwards AD, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 2009, 361:1349-1358.
14. Tsuchida TN, Wusthoff CJ, Shellhaas RA, et al. American clinical neurophysiology society standardized EEG terminology and categorization for the description of continuous EEG monitoring in neonates. J Clin Neurophysiol 2013, 30:161-173.
15. Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med 1999, 341:485-489.
16. Boylan GB, Rennie JM, Chorley G, et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology 2004, 62:486-488.
17. Zohar S, O'Quigley J Optimal designs for estimating the most successful dose. Stat Med 2006, 25:4311-4320.
18. Pons G, Tréluyer JM, Dimet J, Merlé Y Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates. Ther Drug Monit 2002, 24:9-14.
19. Pressler RM, Mangum B Newly emerging therapies for neonatal seizures. Semin Fetal Neonatal Med 2013, 18:216-223.
20. Silverstein FS, Ferriero DM Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol 2008, 39:77-79.
21. Kahle KT, Barnett SM, Sassower KC, Staley KJ Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the NA+-K+-2Cl- cotransporter NKCC1. J Child Neurol 2009, 24:572-576.
22. Muramatsu K, Fukuda A, Togari H, Wada Y, Nishino H Vulnerability to cerebral hypoxic-ischemic insult in neonatal but not in adult rats is in parallel with disruption of the blood-brain barrier. Stroke 1997, 28:2281-2288.
23. Robertson NJ, Cox IJ, Cowan FM, Counsell SJ, Azzopardi D, Edwards AD Cerebral intracellular lactic alkalosis persisting months after neonatal encephalopathy measured by magnetic resonance spectroscopy. Pediatr Res 1999, 46:287-296.
24. Shankaran S, Laptook AR, Ehrenkranz RA, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med 2005, 353:1574-1584.
25. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev 2013, 1. CD003311.
26. Smit E, Liu X, Gill H, Sabir H, Jary S, Thoresen M Factors associated with permanent hearing impairment in infants treated with therapeutic hypothermia. J Pediatr 2013, 163:995-1000.
27. Zimmerman E, Lahav A Ototoxicity in preterm infants: effect of genetics, aminoglycosides and loud environmental noise. J Perinatol 2013, 33:3-8.
28. Brummett RE, Bendrick T, Himes D Comparative ototoxicity of bumetanide and furosemide when used in combination with kanamycin. J Clin Pharmacol 1981, 21:628-636.
29. Delpire E, Lu J, England R, Dull C, Thorne T Deafness and imbalance associated with inactivation of the secretory Na-K-2Cl co-transporter. Nat Genet 1999, 22:192-195.
30. Taylor RR, Nevill G, Forge A Rapid hair cell loss: a mouse model for cochlear lesions. J Assoc Res Otolaryngol 2008, 9:44-64.
31. Wang T, Yang YQ, Karasawa T, et al. Bumetanide hyperpolarizes madin-darby canine kidney cells and enhances cellular gentamicin uptake by elevating cytosolic Ca(2+) thus facilitating intermediate conductance Ca(2+)activated potassium channels. Cell Biochem Biophys 2013, 65:381-398.
32. Lin CD, Kao MC, Tsai MH, et al. Transient ischemia/hypoxia enhances gentamicin ototoxicity viacaspase-dependent cell death pathway. Lab Invest 2011, 91:1092-1106.